News

This indication is approved under accelerated approval. Continued approval for this indication may be contingent upon verification of clinical benefit in subsequent trials. With this approval, BLINCYTO becomes

The multi-year grants that worth about $3.5m will be used for the projects that focus on hepatitis B virus (HBV) and hepatitis C virus (HCV) infection in high-risk

The collaboration will focus on the delivery of muscle-protein fusions, and treatment of multiple indications, in the fields of muscular dystrophies, glycogen storage diseases, myopathies and enzyme-deficiency disorders.

The identity of the pharmaceutical company and its target therapy, which is approved in the U.S and Europe for the treatment of a high prevalence disease of the

Due to its safety profile, the use of Lemtrada should generally be reserved for patients who have had an inadequate response to two or more drugs indicated for

Xyrem (sodium oxybate) oral solution, CIII, is indicated to treat cataplexy in narcolepsy and for the treatment of excessive daytime sleepiness (EDS) in narcolepsy. The drug is the

The company plans to follow up by submitting a briefing package on a later date in support of a pre-IND meeting to review the company’s proposed strategy and

The company has also completed a Phase II trial of ZP-PTH to treat severe osteoporosis as well as intends to carry out Phase III development. As part of

Since 1998, Priftin has been approved in combination with one or more antituberculosis drugs, to treat active pulmonary TB caused by Mycobacterium tuberculosis. The approval was based in